Pfizer general counsel is out
Pfizer's general counsel Amy Schulman is leaving the company. The drugmaker announced Tuesday that Schulman, who was supposed to head up the company's vaccines and oncology division, will not step into the role and is leaving her positions both as general counsel and as part of the company's executive leadership team.
Instead, Albert Bourla will be group president of the vaccines, oncology and consumer healthcare business when it becomes an official financial entity within Pfizer in 2014. Susan Silbermann has been named president of the global vaccines business. Titles for Bourla and Silbermann go into effect next year.
The company said Schulman's departure was part of a mutual agreement.